FFO
XERS icon

Fortitude Family Office’s Xeris Biopharma Holdings XERS Stock Holding History

Fortitude Family Office’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.01K Hold
1,553
– – ﹤0.01% 698
2025
Q4 		$12.2K Hold
1,553
– – ﹤0.01% 518
2025
Q3 		$12.6K Hold
1,553
– – ﹤0.01% 494
2025
Q2 		$7.25K Sell
1,553
-118
-7% -$541 ﹤0.01% 660
2025
Q1 		$9.17K Hold
1,671
– – ﹤0.01% 558
2024
Q4 		$5.67K Hold
1,671
– – ﹤0.01% 802
2024
Q3 		$4.76K Hold
1,671
– – ﹤0.01% 807
2024
Q2 		$3.76K Sell
1,671
-638
-28% -$1.29K ﹤0.01% 680
2024
Q1 		$5.1K Hold
2,309
– – ﹤0.01% 601
2023
Q4 		$5.43K Buy
+2,309
New +$4.26K ﹤0.01% 580

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fortitude Family Office's XERS Position: Q1 2026 in Review

Fortitude Family Office held its Xeris Biopharma Holdings (XERS) position steady in Q1 2026 at 1,553 shares worth $9.01K. The position accounts for ﹤0.01% of the portfolio, ranked #698.

Fortitude Family Office first reported a position in XERS in Q4 2023 and has held it in 10 quarters since. The position peaked at $12.6K in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Fortitude Family Office held 1,553 shares of Xeris Biopharma Holdings worth $9.01K as of Q1 2026.
  • Fortitude Family Office left its Xeris Biopharma Holdings share count unchanged in Q1 2026.
  • Xeris Biopharma Holdings made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #698 holding.
  • Fortitude Family Office first reported a position in Xeris Biopharma Holdings in Q4 2023 and has held it in 10 quarters since.
  • Fortitude Family Office's Xeris Biopharma Holdings position peaked at $12.6K in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.